Research Analysis · Health & function
ACCORD’s intensive glucose target increased mortality and was stopped early
In 10,251 adults with type 2 diabetes and high cardiovascular risk, an intensive multi-drug strategy targeting near-normal glycated hemoglobin did not significantly reduce the primary cardiovascular outcome and increased all-cause mortality.
By Lois Rune
Published August 26, 2026 · Updated August 26, 2026 · AI-assistance disclosure
Evidence scope
Human cardiovascular events, mortality and safety · large randomized trial
No significant primary benefit, with excess mortality
ACCORD reached a median HbA1c of 6.4% versus 7.5%, but the primary cardiovascular outcome was not significantly reduced. All-cause mortality was higher in the intensive group, so that strategy was stopped early.
What ACCORD tested
ACCORD randomized 10,251 adults with established type 2 diabetes and high cardiovascular risk to an intensive multi-drug strategy targeting HbA1c below 6% or a standard target of 7.0% to 7.9%. Median achieved HbA1c was 6.4% and 7.5%, respectively.
The benefit and harm results
The primary cardiovascular outcome occurred 352 times with intensive treatment and 371 times with standard treatment (hazard ratio 0.90; P=0.16). There were 257 deaths in the intensive group and 203 in the standard group (hazard ratio 1.22; P=0.04).
Safety and interpretation
Severe hypoglycemia requiring assistance and weight gain above 10 kilograms were more frequent with intensive treatment. A later ACCORD analysis did not establish hypoglycemia as the mechanism for excess mortality. ADVANCE tested a different glucose-control strategy and did not reproduce the mortality signal, so ACCORD should not be generalized to every glycemic target, drug or patient.
Funding, conflicts and follow-up
ACCORD was funded by NIH and CDC; manufacturers supplied drugs or equipment, and multiple authors disclosed industry relationships. Longer follow-up attenuated the mortality difference but did not reverse the original safety decision.
Sources and editorial method
Evidence review was completed separately from prose drafting across three documented passes. Primary identifiers, trial status, corrections, funding, conflicts, limitations and later context were checked before publication. See the governed issue record.
More metabolic-health trial outcomes
A lifestyle trial with a neutral primary cardiovascular result
Look AHEAD improved weight and risk factors—not cardiovascular event rates
In 5,145 adults with type 2 diabetes and overweight or obesity, intensive lifestyle intervention produced greater sustained weight loss and improved several risk factors. It did not significantly reduce the trial’s primary cardiovascular outcome.
Evidence scopeHuman cardiovascular events and function · large randomized trial
A prevention trial with longer follow-up and different treatment intensity
DPP prevention effects persisted for 15 years—without an overall microvascular difference
Among adults at high risk for type 2 diabetes, the DPP lifestyle and metformin groups still had lower cumulative diabetes incidence after 15 years. The randomized groups did not differ significantly in the study’s aggregate microvascular outcome.
Evidence scopeHuman diabetes incidence and microvascular outcomes · long randomized follow-up
Publication history
Published August 26, 2026 after three research passes, claim-level evidence review, editorial review and deterministic source checks. No correction or retraction affecting the central result was identified at publication.